#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurodermatitis Infantile spasms Immunodeficiency congenital Mitochondrial DNA depletion Squamous cell carcinoma of the oral cavity Non-Hodgkin's lymphoma refractory Wiskott-Aldrich syndrome Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Pulmonary sarcoidosis Hodgkin's disease Cardiac failure acute Scedosporium infection Congenital generalised lipodystrophy Round cell liposarcoma Monogenic diabetes More trials…

    Learn about Rare Diseases

    Hereditary motor and sensory neuropathy Leiomyosarcoma – Trials in Disease Gaucher’s disease type III – Treatment Alport’s syndrome – Diagnostics Rhabdoid tumour – Life with Disease Haemophilia A without inhibitors Tuberous sclerosis complex – Treatment Bronchopulmonary dysplasia – Basic Information Wiskott-Aldrich syndrome – Treatment Cerebral arteriovenous malformation haemorrhagic – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mercaptamine ZINC Ro7790121 Dexamethasone Acetate Ph. Eur. Clenbuterol Hydrochloride Pertuzumab Sodium Nitrite Nystatin LY3848575 Gsk3739937 Mb-Cart20.1 Trametinib Ucart22 Obicetrapib Lumateperone Sodium Butyrate Gen1046 GRNA1599 Neflamapimod Bi 706321 More therapies…

    Learn about Your Condition

    Thalassaemia Multiple sclerosis relapse Insulin resistance Deep vein thrombosis Dry mouth Gallbladder cancer Bile duct adenocarcinoma Metastatic glioma Eye pain Acquired ATTR amyloidosis Cervix carcinoma stage I Sinus rhythm Vulval cancer Immune-mediated myositis Hernia repair More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study Using Fluorescent Adalimumab and Risankizumab to See How These Drugs Work in Patients with Inflammatory Bowel Disease

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Inflammatory bowel disease
    Investigated Drugs:
    • Risankizumab
    • Adalimumab
    The Netherlands

  • A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein

    Recruiting

    2 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • INCB123667
    Belgium Spain

  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Study of icotrokinra for adults with moderately to severely active Crohn’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • A study testing gene therapy with Dream01 and imatinib for patients with severe sickle cell disease to improve red blood cell production

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Imatinib
    France

  • Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Durvalumab
    • Nivolumab
    Austria Belgium Denmark France Germany Greece +6
Previous Page
1 … 89 90 91 92 93 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!